ClinicalTrials.gg
CompletedNCT01761266Updated Apr 5, 2022Results posted

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Phase 3 interventional study of Lenvatinib and Sorafenib in Hepatocellular Carcinoma (HCC), sponsored by Eisai Limited. Completed at 188 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
954
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
Largest of 121
954 · median 48
Started
2013
the only one that year
Phase 3
13 of 121
4 open now
Registered
2nd of 121
by date

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one has the largest enrollment, is the only one that started in 2013, is one of 13 in phase 3, and was the 2nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • Hepatocellular Carcinoma
  • Neoplasms
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Participants must have confirmed diagnosis of unresectable HCC with any of the following criteria:

    • or cytologically confirmed diagnosis of HCC.
    • Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or with chronic or C infection criteria
  2. At least one measurable target lesion according to modified () meeting the following criteria:

    • Hepatic lesion
    1. The lesion can be accurately measured in at least one dimension as >=1.0 centimeter (cm) (viable tumor for typical; and longest diameter for atypical), and
    2. The lesion is suitable for repeat measurement.

      • Nonhepatic lesion
    3. Lymph node (LN) lesion that measures at least one dimension as >=1.5 cm in the short axis, except for porta hepatis LN that measures >=2.0 cm in the short axis.
    4. Non-nodal lesion that measures >=1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
  3. Participants categorized to stage B (not applicable for transarterial chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system.
  4. Adequate bone marrow function, defined as:

    • (ANC) >=1.5 X 10\^9 per liter (/L)
    • (Hb) >=8.5 gram per deciliter (g/dL)
    • count >=75 X 10\^9/L.
  5. Adequate liver function, defined as:

    • Albumin >=2.8 g/dL
    • less than or equal to (\<=) 3.0 mg/dL
    • (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) \<=5 X the (ULN).
  6. Adequate blood coagulation function, defined as (INR) \<=2.3.
  7. Adequate renal function defined as greater than (>) 40 milliliter per minute (mL/min) calculated per the Cockcroft and Gault formula.
  8. Adequate pancreatic function, defined as amylase and lipase \<=1.5 X ULN.
  9. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP \<=150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive therapy within 1 week prior to the Cycle1/Day1.
  10. score A.
  11. (ECOG)- performance status (PS) 0 or 1.
  12. Males or females aged at least 18 years (or any age >18 years as determined by country legislation) at the time of .
  13. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of BhCG).

    A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.

  14. All females will be considered to be of unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  15. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of (e.g., total abstinence, an intrauterine device, a double barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
  16. Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.
  17. Provide written informed consent.
  18. Willing and able to comply with all aspects of the protocol.

Exclusion Criteria

  1. Imaging findings for HCC corresponding to any of the following:

    • HCC with >=50 percent liver occupation
    • Clear invasion into the bile duct
    • Portal vein invasion at the main portal branch (Vp4).
  2. Participants who have received any systemic chemotherapy, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic anticancer agents, including lenvatinib, for advanced/unresectable HCC. Note: Participants who have received local hepatic injection chemotherapy are eligible.
  3. Participants who have received any anticancer therapy (including surgery, percutaneous ethanol injection, radio frequency ablation, transarterial [chemo] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production, eg, granulocyte colony-stimulating factor [G-CSF]) within 28 days prior to randomization.
  4. Participants who have not recovered from toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as \< Grade 2 severity per Version 4.0 (CTCAE v4.0).
  5. Significant cardiovascular impairment: history of congestive heart failure > (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.
  6. Prolongation of interval (QTc) interval to >480 millisecond (ms)
  7. Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator.
  8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, eg, warfarin or similar agents. Treatment with low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted. Antiplatelet agents are prohibited throughout the study.
  9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization.
  10. Gastric or esophageal varices that require interventional treatment within 28 days prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective beta-blocker) is permitted.
  11. Active (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 36 months.
  12. Participants whose only target lesion(s) is in bone will be excluded.
  13. Meningeal carcinomatosis.
  14. Any history of or current brain or subdural .
  15. Participants having >1+ proteinuria on urine dipstick testing will undergo a 24-hour urine collection for quantitative assessment of proteinuria. Participants with a urine protein >=1g/24 hours will be ineligible.
  16. Surgical arterial-portal venous shunt or arterial-venous shunt.
  17. Any medical or other condition that in the opinion of the investigator would preclude the participant's participation in a clinical study.
  18. Known intolerance to lenvatinib or sorafenib (or any of the ).
  19. (HIV) positive or active infection requiring treatment (except for hepatitis virus).
  20. Any history of drug or alcohol dependency or abuse within the prior 6 months.
  21. Any participant who cannot be evaluated by either triphasic liver computed tomography (CT) or triphasic liver Magnetic resonance imaging (MRI) because of allergy or other to both CT and MRI contrast agents.
  22. Major surgery within 3 weeks prior to randomization or scheduled for surgery during the study.
  23. Participants has had a liver transplant.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
954 participants (actual)

Study arms

  • Active comparator
    Lenvatinib

    Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

    Drug: Lenvatinib

  • Active comparator
    Sorafenib

    Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

    Drug: Sorafenib

Interventions

  • 12 mg (or 8 mg) once daily (QD) oral dosing.

    Also known as: E7080, Lenvima

  • 400 mg twice daily (BID) oral dosing.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.

    Time frame: From date of randomization until date of death from any cause (approximately up to 3.8 years)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)

  2. Time to Progression (TTP)

    TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)

  3. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)

  4. Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)

  5. Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)

    The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)

  6. Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)

    The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)

  7. Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib

    AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)

Other outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

    Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)

  2. Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

    Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)

  3. Percent Change From Baseline in Serum Biomarker

    The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

    Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)

07

Results

Posted Sep 25, 2018

Participant flow

Participants took part in the study at 154 investigative sites in Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Malaysia, Philippines, Poland, Russia, Singapore, Spain, Taiwan, Thailand, United Kingdom, and the United States from 1 March 2013 to 10 March 2021.

Participant flow — Overall Study
MilestoneLenvatinibSorafenib
Started478476
Treated476475
Completed00
Not completed478476
Withdrew: Death415402
Withdrew: Lost to follow-up812
Withdrew: Withdrawal by subject1410
Withdrew: Sponsor decision4152

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.

Time frame:
From date of randomization until date of death from any cause (approximately up to 3.8 years)
Reported as:
Median · months
Overall Survival (OS)
monthsLenvatinibSorafenib
Overall Survival (OS)13.6 ± 12.112.3 ± 10.4
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsLenvatinibSorafenib
Progression Free Survival (PFS)7.4 ± 6.93.7 ± 3.6
SecondaryTime to Progression (TTP)

TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)
Reported as:
Median · months
Time to Progression (TTP)
monthsLenvatinibSorafenib
Time to Progression (TTP)8.9 ± 7.43.7 ± 3.6
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsLenvatinibSorafenib
Objective Response Rate (ORR)24.1 ± 20.29.2 ± 6.6
SecondaryTime to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Reported as:
Median · months
Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
monthsLenvatinibSorafenib
Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)1.7 ± 1.051.8 ± 1.05
SecondaryTime to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)

The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Reported as:
Median · months
Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)
monthsLenvatinibSorafenib
Fatigue1.9 ± 1.811.8 ± 1.74
Jaundice4.6 ± 3.723.7 ± 2.86
Body Image2.8 ± 2.731.9 ± 1.84
Nutrition4.1 ± 3.682.8 ± 2.04
Pain2.7 ± 1.972.8 ± 2.73
Fever5.5 ± 4.573.7 ± 2.99
Sex Life7.4 ± 5.466.7 ± 4.60
Abdominal swelling7.4 ± 5.527.4 ± 5.46
SecondaryTime to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)

The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Reported as:
Median · months
Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)
monthsLenvatinibSorafenib
VAS2.8 ± 2.171.9 ± 1.84
HUI2.8 ± 1.971.9 ± 1.84
SecondaryArea Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib

AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.

Time frame:
Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
nanogram*hour per milliliter (ng*h/mL)Lenvatinib 8 mgLenvatinib 12 mg
Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib1969.6 ± 743.02120.9 ± 685.6
Other pre-specifiedDisease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

Time frame:
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsLenvatinibSorafenib
Disease Control Rate (DCR)75.5 ± 71.760.5 ± 56.1
Other pre-specifiedClinical Benefit Rate (CBR)

CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

Time frame:
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsLenvatinibSorafenib
Clinical Benefit Rate (CBR)59.0 ± 54.638.4 ± 34.1
Other pre-specifiedPercent Change From Baseline in Serum Biomarker

The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.

Time frame:
Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)
Reported as:
Median · percent change
Percent Change From Baseline in Serum Biomarker
percent changeLenvatinibSorafenib
ANG 2: Cycle 1 Day 15-28.1 ± 15.948.9 ± 23.96
ANG 2: Cycle 2 Day 1-28.8 ± 16.53-0.9 ± 24.06
ANG 2: Cycle 3 Day 1-32.2 ± 23.230.5 ± 26.62
ANG 2: Cycle 4 Day 1-35.6 ± 22.91-4.5 ± 20.05
ANG 2: Cycle 5 Day 1-38.9 ± 19.837.0 ± 23.25
ANG 2: Cycle 6 Day 1-36.7 ± 23.59-3.6 ± 24.82
ANG 2: Cycle 7 Day 1-41.4 ± 21.201.0 ± 32.83
ANG 2: Cycle 8 Day 1-40.2 ± 25.33-6.7 ± 31.26
ANG 2: Cycle 9 Day 1-39.6 ± 14.04-1.1 ± 29.68
ANG 2: Off-Treatment11.7 ± 99.1316.8 ± 27.88
FGF19: Cycle 1 Day 1575.0 ± 155.011.3 ± 83.65
FGF19: Cycle 2 Day 166.5 ± 134.2636.6 ± 119.65
FGF19: Cycle 3 Day 186.9 ± 123.8522.8 ± 70.58
FGF19: Cycle 4 Day 1208.1 ± 602.1146.8 ± 214.14
FGF19: Cycle 5 Day 1152.8 ± 228.37-1.0 ± 40.36
FGF19: Cycle 6 Day 1119.8 ± 203.8126.9 ± 67.13
FGF19: Cycle 7 Day 164.4 ± 101.97-5.9 ± 57.39
FGF19: Cycle 8 Day 195.8 ± 135.3153.9 ± 113.79
FGF19: Cycle 9 Day 1159.3 ± 202.0056.6 ± 109.46
FGF19: Off-Treatment140.1 ± 270.739.0 ± 64.17
FGF 21: Cycle 1 Day 1522.0 ± 75.224.0 ± 43.14
FGF 21: Cycle 2 Day 115.7 ± 77.4418.6 ± 57.18
FGF 21: Cycle 3 Day 138.3 ± 38.349.4 ± 76.43
FGF 21: Cycle 4 Day 142.9 ± 145.4332.8 ± 70.63
FGF 21: Cycle 5 Day 141.0 ± 95.9731.1 ± 43.15
FGF 21: Cycle 6 Day 152.6 ± 168.2223.2 ± 40.90
FGF 21: Cycle 7 Day 163.4 ± 128.3423.7 ± 53.84
FGF 21 : Cycle 8 Day138.3 ± 115.5317.0 ± 68.51
FGF 21: Cycle 9 Day159.1 ± 108.3968.9 ± 103.55
FGF 21: Off-Treatment141.4 ± 340.51104.9 ± 183.28
FGF 23: Cycle 1 Day1523.9 ± 49.01-16.3 ± 36.14
FGF 23: Cycle 2 Day 120.9 ± 56.91-6.2 ± 48.18
FGF 23: Cycle 3 Day 125.5 ± 45.2717.3 ± 75.25
FGF 23: Cycle 4 Day 129.5 ± 48.3814.2 ± 49.29
FGF 23: Cycle 5 Day 129.6 ± 63.691.0 ± 47.28
FGF 23: Cycle 6 Day 126.3 ± 54.57-10.6 ± 46.15
FGF 23: Cycle 7 Day 131.5 ± 57.440.7 ± 46.95
FGF 23: Cycle 8 Day 138.1 ± 67.352.8 ± 43.84
FGF 23: Cycle 9 Day 123.2 ± 62.580.5 ± 38.74
FGF 23: Off-Treatment17.8 ± 73.5914.2 ± 47.11
PIVKA-II: Cycle 1 Day 1580.0 ± 171.41166.9 ± 256.04
PIVKA-II: Cycle 2 Day 1169.7 ± 329.33243.8 ± 416.82
PIVKA-II: Cycle 3 Day 1252.4 ± 611.40218.7 ± 281.45
PIVKA-II: Cycle 4 Day 1371.7 ± 812.45196.2 ± 348.80
PIVKA-II: Cycle 5 Day 1628.2 ± 1752.64369.5 ± 766.59
PIVKA-II: Cycle 6 Day 1648.7 ± 2746.41415.7 ± 554.27
PIVKA-II: Cycle 7 Day 1184.8 ± 352.75703.6 ± 1226.58
PIVKA-II: Cycle 8 Day 1277.8 ± 481.53724.0 ± 1257.87
PIVKA-II: Cycle 9 Day 1318.8 ± 577.21859.1 ± 1492.93
PIVKA-II: Off-Treatment809.3 ± 1827.42272.5 ± 489.60
VEGF: Cycle 1 Day 15157.5 ± 300.2197.4 ± 118.43
VEGF: Cycle 2 Day 1128.9 ± 333.8594.0 ± 180.80
VEGF: Cycle 3 Day 197.7 ± 162.3966.0 ± 124.58
VEGF: Cycle 4 Day 1113.4 ± 231.1976.1 ± 111.20
VEGF: Cycle 5 Day 1132.4 ± 249.59116.2 ± 215.57
VEGF: Cycle 6 Day 1113.1 ± 219.36130.9 ± 341.12
VEGF: Cycle 7 Day 1133.1 ± 383.4396.9 ± 173.77
VEGF: Cycle 8 Day 1148.7 ± 349.58181.1 ± 399.67
VEGF: Cycle 9 Day 1129.6 ± 215.05135.6 ± 267.61
VEGF: Off-Treatment127.1 ± 266.64147.8 ± 304.31

Adverse events

Collected over All treatment-emergent adverse events were collected from first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 8 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib415/478 (86.8%)209/476 (43.9%)469/476 (98.5%)
Sorafenib402/476 (84.5%)149/475 (31.4%)469/475 (98.7%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventLenvatinibSorafenib
Hepatic encephalopathyNervous system disorders21/4763/475
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/47614/475
Hepatic failureHepatobiliary disorders14/4768/475
AscitesGastrointestinal disorders12/47612/475
Abdominal painGastrointestinal disorders6/47611/475
Decreased appetiteMetabolism and nutrition disorders11/4762/475
DiarrhoeaGastrointestinal disorders8/4762/475
Oesophageal varices haemorrhageGastrointestinal disorders7/4765/475
Jaundice cholestaticHepatobiliary disorders7/4764/475
Blood bilirubin increasedInvestigations7/4761/475
Most frequent other events
Showing 10 of 51
Most frequent other events
EventLenvatinibSorafenib
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders128/476246/475
DiarrhoeaGastrointestinal disorders186/476223/475
HypertensionVascular disorders200/476147/475
Decreased appetiteMetabolism and nutrition disorders162/476126/475
Weight decreasedInvestigations149/476108/475
FatigueGeneral disorders141/476120/475
AlopeciaSkin and subcutaneous tissue disorders15/476120/475
ProteinuriaRenal and urinary disorders117/47655/475
DysphoniaRespiratory, thoracic and mediastinal disorders113/47657/475
NauseaGastrointestinal disorders90/47671/475

Baseline characteristics

The full analysis set (FAS) included all participants who were randomized.

Age, Continuous
Age, Continuous(years)LenvatinibSorafenibTotal
Mean61.3 ± 11.6961.2 ± 12.0161.3 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)LenvatinibSorafenibTotal
Female7375148
Male405401806
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LenvatinibSorafenibTotal
Hispanic or Latino61117
Not Hispanic or Latino472465937
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LenvatinibSorafenibTotal
American Indian or Alaska Native101
Asian334326660
Native Hawaiian or Other Pacific Islander011
Black or African American7613
White135141276
Other123
08

Study locations

188 sites
  • Facility # 1
    Los Angeles, California, United States
  • Facility # 1
    Sacramento, California, United States
  • Facility # 1
    San Francisco, California, United States
  • Facility # 1
    Washington, District of Columbia, United States
  • Facility # 1
    Tampa, Florida, United States
  • Facility # 1
    Duluth, Georgia, United States
  • Facility # 1
    Lawrenceville, Georgia, United States
  • Facility # 1
    Baltimore, Maryland, United States
  • Facility # 1
    Detroit, Michigan, United States
  • Facility # 1
    Kansas City, Missouri, United States
  • Facility # 1
    Saint Louis, Missouri, United States
  • Facility # 1
    East Orange, New Jersey, United States
  • Facility # 1
    Brooklyn, New York, United States
  • Facility # 1
    Lake Success, New York, United States
  • Facility # 1
    New York, New York, United States
  • Facility # 1
    Charlotte, North Carolina, United States
  • Facility # 1
    Durham, North Carolina, United States
  • Facility # 1
    Portland, Oregon, United States
  • Facility # 1
    Austin, Texas, United States
  • Facility # 1
    Lubbock, Texas, United States
  • Facility # 1
    Seattle, Washington, United States
  • Facility # 1
    Camperdown, New South Wales, Australia
  • Facility # 1
    Wentworthville, New South Wales, Australia
  • Facility # 1
    Woolloongabba, Queensland, Australia
  • Facility # 1
    Fitzroy, Victoria, Australia
  • Facility # 1
    Melbourne, Victoria, Australia
  • Facility # 2
    Melbourne, Victoria, Australia
  • Facility # 1
    Nedlands, Western Australia, Australia
  • Facility # 1
    Bruxelles, Belgium
  • Facility # 1
    Edegem, Belgium
  • Facility # 1
    Liege, Belgium
  • Facility # 1
    Ottawa, Ontario, Canada
  • Facility # 1
    Hefei, Anhui, China
  • Facility # 1
    Beijing, Beijing, China
  • Facility # 2
    Beijing, Beijing, China
  • Facility # 3
    Beijing, Beijing, China
  • Facility # 1
    Chongqing, Chongqing, China
  • Facility # 1
    Fuzhou, Fujian, China
  • Facility # 2
    Fuzhou, Fujian, China
  • Facility # 1
    Guangzhou, Guangdong, China
  • Facility # 1
    Harbin, Heilongjiang, China
  • Facility # 1
    Changsha, Hunan, China
  • Facility # 1
    Nanjing, Jiangsu, China
  • Facility # 1
    Suzhou, Jiangsu, China
  • Facility # 1
    Changchun, Jilin, China
  • Facility # 1
    Dalian, Liaoning, China
  • Facility # 1
    Jinan, Shandong, China
  • Facility # 1
    Shanghai, Shanghai, China
  • Facility # 3
    Shanghai, Shanghai, China
  • Facility # 1
    Xi'an, Shanxi, China
  • Facility # 2
    Xi'an, Shanxi, China
  • Facility # 1
    Hangzhou, Zhejiang, China
  • Facility # 1
    Tianjin, Zhejiang, China
  • Facility # 1
    Nice Cedex 3, Alpes Maritimes, France
  • Facility # 1
    Pessac Cedex, Gironde, France
  • Facility # 1
    Pessac, Gironde, France
  • Facility # 1
    Toulouse, Haute Garonne, France
  • Facility # 1
    Montpellier cedex 5, Herault, France
  • Facility # 1
    Rennes cedex, Ille Et Vilaine, France
  • Facility # 1
    Vandoeuvre les Nancy, Meurthe Et Moselle, France
  • Facility # 1
    Amiens cedex 1, Somme, France
  • Facility # 1
    Creteil Cedex, Val De Marne, France
  • Facility # 1
    Bordeaux, France
  • Facility # 1
    Lille cedex, France
  • Facility # 1
    Lyon, France
  • Facility # 1
    Nord, 59037, France
  • Facility # 1
    Paris cedex 12, 75020, France
  • Facility # 1
    Paris, 75013, France
  • Facility # 1
    Rhone, France
  • Facility # 1
    Heidelberg, Baden Wuerttemberg, Germany
  • Facility # 1
    Tuebingen, Baden Wuerttemberg, Germany
  • Facility # 1
    Marburg, Hessen, Germany
  • Facility # 1
    Hannover, Niedersachsen, Germany
  • Facility # 1
    Essen, Nordrhein Westfalen, Germany
  • Facility # 1
    Koeln, Nordrhein Westfalen, Germany
  • Facility # 1
    Mainz, Rheinland Pfalz, Germany
  • Facility # 1
    Hong Kong, Hong Kong
  • Facility # 2
    Hong Kong, Hong Kong
  • Facility # 3
    Hong Kong, Hong Kong
  • Facility # 1
    Kowloon, Hong Kong
  • Facility # 1
    Petach Tikva, Israel
  • Facility # 1
    Petah Tiqwa, Israel
  • Facility # 1
    Torrette, Ancona, Italy
  • Facility # 1
    Bari, Italy
  • Facility # 1
    Benevento, Italy
  • Facility # 1
    Bologna, Italy
  • Facility # 1
    Napoli, Italy
  • Facility # 2
    Napoli, Italy
  • Facility # 1
    Palermo, Italy
  • Facility # 1
    Roma, Italy
  • Facility # 1
    Nagoya, Aichi, Japan
  • Facility # 1
    Kashiwa, Chiba, Japan
  • Facility # 1
    Matsuyama, Ehime, Japan
  • Facility # 1
    Kurume, Fukuoka, Japan
  • Facility # 1
    Sapporo, Hokkaido, Japan
  • Facility # 2
    Sapporo, Hokkaido, Japan
  • Facility # 1
    Nishinomiya, Hyogo, Japan
  • Facility # 1
    Kanazawa, Ishikawa, Japan
  • Facility # 1
    Kawasaki, Kanagawa, Japan
  • Facility # 1
    Yokohama, Kanagawa, Japan

Showing the first 100 of 188 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, Lopez CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20. PubMed 36341767 ↗
  • Huynh J, Cho MT, Kim EJ, Ren M, Ramji Z, Vogel A. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol. 2022 Aug 24;14:17588359221116608. doi: 10.1177/17588359221116608. eCollection 2022. PubMed 36051472 ↗
  • Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2. PubMed 34087115 ↗
  • Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol. 2021 Jun;56(6):570-580. doi: 10.1007/s00535-021-01785-0. Epub 2021 May 4. PubMed 33948712 ↗
  • Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020 Jun;122(12):1754-1759. doi: 10.1038/s41416-020-0817-7. Epub 2020 Apr 8. PubMed 32265508 ↗
  • Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. PubMed 31720835 ↗
  • Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum In: Br J Cancer. 2019 Oct;121(7):625. doi: 10.1038/s41416-019-0534-2. PubMed 31249394 ↗
  • Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed 29433850 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Nov 2016, 44 months.

Results were first posted in Sep 2018, 1 year 10 months after primary completion. A results delay was requested in Jan 2018.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 44 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2013
First posted
Jan 4, 2013
StartActual
Mar 1, 2013
Primary completionActual
Nov 13, 2016
CompletionActual
Mar 10, 2021
Results delay requested
Jan 18, 2018
Results first posted
Sep 25, 2018
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01761266
Lead sponsor
Eisai Limited
Responsible party
Sponsor
First posted
Jan 4, 2013
Start date
Mar 1, 2013
Primary completion
Nov 13, 2016
Completion
Mar 10, 2021
Results posted
Sep 25, 2018
Last update
Apr 5, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion